靶向肿瘤对比剂MT218的理化性质、药代动力学、生物分布、毒性及对比增强癌症MRI评估
该临床前研究按照美国食品药品监督管理局指南,评估了靶向细胞外结构域B纤连蛋白的肽类钆对比剂MT218的理化性质、药代动力学、清除、安全性及肿瘤特异性MR成像。MT218具有高r1和r2弛豫率、良好的理化性质和安全性,在大鼠和小鼠多种癌症类型中以降低的剂量产生有效的肿瘤增强。
要点
- MT218在1.4 T下纯水中r1为5.43 mM-1s-1、r2为7.40 mM-1s-1,磷酸盐缓冲液中r1为6.58、r2为8.87 mM-1s-1。
- MT218与细胞外结构域B片段结合亲和力为3.45 μM,生理条件下无Gd(III)螯合物解离。
- 0.04 mmol/kg剂量下,MT218在细胞外结构域B纤连蛋白丰富的肿瘤中使对比噪声比最高增加7倍,持续至少30分钟。
核心结论
- 临床前评估表明,靶向对比剂MT218具有高r1和r2弛豫率、令人满意的理化性质、药代动力学和安全性特征,并在大鼠和小鼠多种癌症类型中以降低的剂量产生有效的肿瘤增强。
研究设计与样本
- 临床前评估按照美国食品药品监督管理局指南进行,包括体外理化性质与安全性靶点分析,以及大鼠前列腺癌异种移植、免疫健全小鼠鼠源胰腺癌同种移植及小鼠肺癌异种移植的MRI研究。
诊断标准与关键数值
- 在1.4 T下,MT218在纯水中r1为5.43 mM-1s-1、r2为7.40 mM-1s-1,在磷酸盐缓冲液中r1为6.58 mM-1s-1、r2为8.87 mM-1s-1,在人血清白蛋白水溶液中r1为6.54 mM-1s-1、r2为8.70 mM-1s-1。
- MT218与细胞外结构域B片段的结合亲和力为3.45 μM。
- MT218的肽段降解半衰期在大鼠、犬和人血浆中分别为1.63、5.85和2.63小时。
- 0.04 mmol/kg剂量下,MT218在细胞外结构域B纤连蛋白丰富的肿瘤中使对比噪声比最高增加7倍,持续至少30分钟。
- MT218在大鼠和犬0.1 mmol/kg剂量下的平均血浆消除半衰期分别为0.31和0.89小时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Preclinical assessments were performed according to the US Food and Drug Administration guidelines to determine the physicochemical properties, pharmacokinetics, clearance, safety, and tumor-specific magnetic resonance (MR) imaging of MT218, a peptidic gadolinium-based MR imaging agent targeting to extradomain B fibronectin for MR molecular imaging of aggressive tumors.
MATERIALS AND METHODS: Relaxivity, chelation stability, binding affinity, safety-related target profiling, and effects on CYP450 enzymes and transporters were evaluated in vitro. Magnetic resonance imaging was performed with rats bearing prostate cancer xenografts, immunocompetent mice bearing murine pancreatic cancer allografts, and mice bearing lung cancer xenografts at different doses of MT218. Pharmacological effects on cardiovascular, respiratory, and central nervous systems were determined in rats and conscious beagle dogs. Pharmacokinetics were tested in rats and dogs. Biodistribution and excretion were studied in rats. Single and repeated dosing toxicity was evaluated in rats and dogs. In vitro and in vivo genotoxicity, in vitro hemolysis, and anaphylactic reactivity were also performed.
RESULTS: At 1.4 T, the r1 and r2 relaxivities of MT218 were 5.43 and 7.40 mM -1 s -1 in pure water, 6.58 and 8.87 mM -1 s -1 in phosphate-buffered saline, and 6.54 and 8.70 mM -1 s -1 in aqueous solution of human serum albumin, respectively. The binding affinity of MT218 to extradomain B fragment is 3.45 μM. MT218 exhibited no dissociation of the Gd(III) chelates under physiological conditions. The peptide degradation half-life ( t1/2 ) of MT218 was 1.63, 5.85, and 2.63 hours in rat, dog, and human plasma, respectively. It had little effect on CYP450 enzymes and transporters. MT218 produced up to 7-fold increase of contrast-to-noise ratios in the extradomain B fibronectin-rich tumors with a dose of 0.04 mmol/kg for at least 30 minutes. MT218 had little pharmacological effect on central nervous, cardiovascular, or respiratory systems. MT218 had a mean plasma elimination half-life ( t1/2 ) of 0.31 and 0.89 hours in rats and dogs at 0.1 mmol/kg, respectively. No detectable Gd deposition was observed in the brain at 6 hours postinjection of MT218 at 0.1 mmol/kg in rats. MT218 was not mutagenic and had no mortality or morbidity in the rats or dogs up to 1.39 and 0.70 mmol/kg/d, respectively. The no observed adverse effect level of MT218 in Sprague-Dawley rats was 1.39 mmol/kg for single dosing and 0.46 mmol/kg/d for repeated dosing. The no observed adverse effect level in dogs was 0.07 mmol/kg/d. MT218 exhibited no genotoxicity, hemolysis, and anaphylactic reactivity.
CONCLUSION: The preclinical assessments showed that the targeted contrast agent MT218 has high r1 and r2 relaxivities, satisfactory physicochemical properties, pharmacokinetic, and safety profiles and produces effective tumor enhancement in multiple cancer types in rats and mice at reduced doses.
引用
- Li, Gao, Jiang, et al. Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218. Invest Radiol. 2022. PMID: 35703463. doi:10.1097/RLI.0000000000000881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。